Bone Marrow Transplantation News

The majority of patients with chronic graft-versus-host disease are unable to discontinue immunosuppressive therapy for more than 1 year, according to retrospective study results presented at TCT Meetings Digital Experience.

Center for International Blood and Marrow Transplant will present awards to two clinicians during this year’s TCT Meetings Digital Experience.

Patients with graft-versus-host disease who developed steroid-related complications required substantial health care resource utilization and incurred considerable costs, according to results presented at TCT Meetings Digital Experience.

American Society for Transplantation and Cellular Therapy will present three awards during this year’s TCT Meetings Digital Experience.

Little is known about the long-term issues facing cancer survivors who received chimeric antigen receptor T-cell therapy, primarily because the therapy is relatively new.

The FDA cleared an investigational new drug application for VOR33, an engineered stem cell therapy for the treatment of patients with acute myeloid leukemia who are at high risk for relapse, according to the agent’s manufacturer.

Sitagliptin significantly reduced incidence of acute graft-versus-host disease after myeloablative allogeneic peripheral blood stem cell transplantation, according to phase 2 study results published in The New England Journal of Medicine.

Ninety percent of patients with relapsed B-cell acute lymphoblastic leukemia after allogeneic stem cell transplantation had complete response to an investigational chimeric antigen receptor T-cell therapy, according to preliminary data.

This year’s virtual ASH Annual Meeting and Exposition featured hundreds of abstracts that spotlighted research advances in blood cancer and benign hematology research.

Belumosudil conferred high overall response rates at two dose levels among patients with chronic graft-versus-host disease, according to results of the phase 2 ROCKstar study presented at the virtual ASH Annual Meeting and Exposition.